// App-Quantinova.ai

65 : Personalising care: the use of anti-drug antibodies and drug trough levels is a safe and cost-effective treatment strategy in spondyloarthritis

Researchers

Presenter

  • S R Dubash

Principal Investigators

  • D Bryer

  • J Fitton

  • A Barr

  • C Wenham

  • H Marzo-Ortega

  • JE Freeston

Medical Centers

  • NIHR Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved